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Letters to the EditorRare statin hepatotoxicity: Convincing evidence based
on breakthrough case studyunlikely to apply to statin hepatotoxicity since prerequisites such
as short duration of exposure of 1–5 weeks, features of overt
hypersensitivity, and prompt response to re-exposure with 1–2
doses [5] are not apparent in the reported cases [1]. However,
the metabolic subtype with items of variable duration of expo-
sure of one week up to 12 months, the absence of clinical features
of hypersensitivity such as rash, fever, and eosinophilia, and the
delayed response to rechallenge of many days or weeks [5] best
ﬁt with cases of idiosyncratic statin hepatotoxicity [1].
The diagnosis of liver injury by drugs and herbs is often cum-
bersome to establish, because surrogate markers are lacking [6]
and new sophisticated diagnostic approaches have not yet
reached the clinical area [7,8]. This is why alternative diagnoses
were found and were described in details in numerous hepato-
toxicity studies upon thorough causality assessment, as summa-
rized previously [6,9]. In the present study [1], however,
primarily missed alternative diagnoses were not mentioned and
should have been provided, because this information is helpful
also as a reminder to clinicians to evaluate the various differential
diagnoses that may otherwise easily be overlooked. For reasons
of transparency, also listed details of individual CIOMS items
for each case with a highly probable or probable causality for
statins would have been appreciated. These few suggestions
should not detract from the excellent quality of this highly appre-
ciated statin hepatotoxicity report [1], as will not by no means
the associated and somewhat irritating editorial comment that
tries to justify ex post own previous unsustainable confusing
statements and detracts from the actual topic of statin hepato-
toxicity existence [10].
Essentially, this breakthrough case study provides convincing
evidence for the existence of rare statin hepatotoxicity and will
certainly facilitate assessments of patients with primarily sus-
pected toxic liver injury associated with the use of statins. Statin
hepatotoxicity is due to idiosyncrasy of the metabolic subtype,
occurs unpredictably and independently of the dose, and is not
preventable. Early recognition and statin discontinuation are
mandatory for risk management to improve overall prognosis.
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The excellent study of Björnsson et al. [1] published in the Febru-
ary 2012 issue of the Journal of Hepatology provides convincing
evidence for the existence of rare statin hepatotoxicity. This
report clearly contradicts previous statements, which labeled sta-
tin hepatotoxicity as a myth and called for a deletion of the pack-
ing inserts that contain information about the problem of
hepatotoxicity [2].
At different assessment levels, the present statin hepatotoxic-
ity study provides several hallmarks [1]. First, impressive is the
high number of 21 hepatotoxicity patients who had a probable
or highly probable causality for statins in 14 and 7 cases, respec-
tively. Second, high causality levels in these 21 cases can only be
achieved by excellent data that were supplied from spontaneous
reports of the Swedish Adverse Drug Reactions Advisory Commit-
tee (SADRAC). Third, the strict deﬁnition of hepatotoxicity
allowed only cases with >5  upper limit of normal (ULN) in ami-
notransferases and/or >2  ULN in alkaline phosphatase to be
included in their study to reduce the risk of false positive signals.
Fourth, with the scale of CIOMS (Council for International Organi-
zations of Medical Sciences), the best available and internation-
ally accepted causality method for hepatotoxicity cases was
used. Fifth, among the seven patients with a highly probable cau-
sality for statins, there were three cases with a conﬁrmed positive
rechallenge test, providing additional support for the existence of
statin hepatotoxicity.
The present report provides the rare chance for liver injury
studies to describe in detail statin hepatotoxicity as a special dis-
ease entity [1]. In previous reports dealing with the characteriza-
tion of hepatotoxicity, the crucial issue was always whether this
approach should also incorporate cases with a possible causality
grading or might better be restricted to cases with highly proba-
ble and probable causality levels [3,4]. In the present study, the
52 cases with a possible causality for statins were also considered
[1]. This raises the question of whether statin hepatotoxicity as
assessed under these conditions exhibits characteristics similar
to those obtained when only data of cases with highly probable
and probable causality levels for statins were used. Calculation
of the incidence of statin hepatotoxicity also depends on whether
cases with a possible causality are included or not.
Statin hepatotoxicity was correctly determined as the classic
idiosyncratic hepatotoxicity [1] and not as intrinsic hepatotoxic-
ity, which is predictable and shows dose dependency, short and
consistent latency period, high incidence among users, and
experimental reproducibility [5]. This contrasts with the idiosyn-
cratic hepatotoxicity with its low incidence among users at nor-
mal doses, long and variable latency period, unpredictability,
dose independency, and lack of reproducibility in experimental
animals [5]. Attempts to subclassify the idiosyncratic hepatotox-
icity by statins into the immunologic or the metabolic subtype
have yet to be reported [1]. The immunologic subtype appearsJournal of Hepatology 2012 vol. 57 j 699–711
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Biliary atresia: Does ethnicity matter?
To the Editor:
We wish to call the readership’s attention to the recent study by
Boonstra et al. [1] on the systematic review that showed that the
incidence and the prevalence of primary sclerosing cholangitis
and primary biliary cirrhosis vary widely based on the geograph-
ical distribution. Further, it was previously observed that the
severity and the incidence of primary sclerosing cholangitis were
inﬂuenced by ethnicity [2,3]. We expanded here the scope of this
methodology to another biliary disease, i.e. biliary atresia (BA),
which is a destructive cholangiopathy of neonates that leads to
biliary cirrhosis. Furthermore, it constitutes a public health issue
as being the main reason for liver transplantation in children.
Incidence of BA differs between studies. We hypothesized
that the incidence of this disease could also be inﬂuenced by
ethnicity. We thus conducted a systematic literature search to
identify articles containing information on the incidence of bil-
iary atresia according to ethnicity. Keywords for the database
search of MEDLINE (1840 to January 2012) were ‘‘biliary atresia’’
and ‘‘incidence’’, which were further cross-linked with either
‘‘ethnic’’ or ‘‘ethnicity’’ or ‘‘racial’’ for the search in Google Scho-
lar (Biology and Medicine only). Of 660 references, 96 appeared
to contain information related to the topic of interest. Refer-
ences were included in this review if all of the following items
were present: time period and location of the study, total live
births and number of infants with biliary atresia according to
ethnic origin. Incidences of BA were retrieved from the included
references, and were plotted on a world map (Fig. 1), which
indicates the highest incidence in French Polynesia. We thus
combined a population-based observation, and studied the inci-
dence of BA over a time period of 30 years (1979–2009) in Poly-
nesians and Caucasians living in French Polynesia. We found
that the incidence of BA at 33.5 per 100,000 live births in Poly-
nesians was signiﬁcantly higher than in Caucasians (p = 0.0075,
Fisher exact test) (Fig. 1). From the systematic review, we
extracted six other studies [4–9] that reported incidence accord-
ing to the ethnic origin of the patients. Incidence was high in
Polynesians [4,5,10] and native Indians/Inuits [5], intermediate
in Asians [6], and low in Caucasians [5,7–9] (Fig. 1). Three of
the six studies enabled calculation of the incidence in people
of different ethnic origins who share the same geographic loca-
tion. We found that the incidence of BA was signiﬁcantly differ-
ent between Caucasians and Polynesian Maoris in New Zealand
[8], Caucasians and native Indians/Inuits in Canada [5], and Cau-
casians and African-Americans in the United States of America
[7] with p-values of 10-7, 10-5 and 0.013, respectively (Chi-
square test results). Thus, our previous ﬁnding that BA was sea-
sonal in French Polynesia [10] suggests that the interplay
between ancestry and environment determines the predisposi-
tion of Polynesians to BA. As pointed out by Boonstra et al.
[1], epidemiological data may help identify etiological factors
for these complex diseases. Because most epidemiological stud-
ies are performed in mixed populations, we propose that future
studies on BA and primary sclerosing cholangitis take into
account the ethnicity.
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